NCT06630221 2025-07-03
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Case Comprehensive Cancer Center
Phase 2 Recruiting
Clinical Trials
4 trialsNCT03844360 2025-03-30
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Shandong University
Phase 4 Recruiting
NCT04600960 2025-02-24
Eltrombopag for Chemotherapy-induced Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05961410 2024-10-18
EPBSCH
National Taiwan University Hospital
Phase 2 Recruiting